Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health (NYSE:BHC) and its dentistry business OraPharma have launched OraTalks, a new podcast series focused on modern dentistry challenges. The inaugural nine-episode season, hosted by industry expert Melissa K. Turner, will explore critical topics including sleep disorders, women's health, and social determinants in oral healthcare.

The podcast aims to address significant oral health challenges, considering that nearly 65 million Americans are affected by gum disease. OraTalks will be available on major platforms like Apple Podcasts and Spotify starting September 29, 2025, with registration available at oratalks.com for exclusive updates.

Bausch Health (NYSE:BHC) has successfully completed its acquisition of DURECT Corporation for $1.75 per share, representing a total upfront cash payment of $63 million. The deal includes potential additional milestone payments of up to $350 million based on net sales achievements.

The acquisition brings DURECT's lead asset larsucosterol, an FDA Breakthrough Therapy-designated epigenetic modulator for alcohol-associated hepatitis (AH), into Bausch Health's hepatology pipeline. A Phase 3 program is being planned to evaluate the treatment's safety and efficacy. Currently, there are no approved therapies for AH, with existing supportive care resulting in approximately 30% mortality within 90 days of hospitalization.

The tender offer secured approximately 19,984,767 shares, representing about 62% of DURECT's outstanding common stock. Following the merger, DURECT has become a wholly owned subsidiary of Bausch Health and will be delisted from Nasdaq.

Bausch Health (NYSE:BHC) and its aesthetic business unit Solta Medical have announced a significant milestone for their Thermage technology, surpassing 5 million skin tightening treatments worldwide.

Thermage, a non-invasive treatment system, uses monopolar radiofrequency energy to stimulate collagen production and tighten skin naturally. It is uniquely positioned as the only non-invasive technology approved for upper and lower eyelid treatments.

The company plans to continue investing in research and development while gathering additional clinical evidence to advance the technology further.

Bausch Health (NYSE:BHC) has announced the extension of its tender offer deadline to acquire DURECT Corporation (NASDAQ:DRRX). The offer, originally set to expire on September 9, 2025, has been extended to September 10, 2025, at 5:00 p.m. New York City time.

The all-cash transaction values DURECT at $1.75 per share, with an upfront consideration of approximately $63 million at closing. The deal includes potential additional milestone payments of up to $350 million based on net sales achievements of larsucosterol, contingent on meeting targets before the earlier of 10 years after first U.S. commercial sale or December 31, 2045.

Bausch Health Canada (NYSE:BHC) announced expanded access to its acne treatment CABTREO™ through the public drug plans of Quebec and Saskatchewan. This follows previous coverage announcements in Ontario, Nova Scotia, and federal programs including NIHB, CSC, and Veterans Affairs Canada.

CABTREO is a Canadian-made triple-combination topical prescription for treating acne vulgaris in patients 12 years and older. It is the first and only Health Canada-approved triple-combination treatment combining an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide) in a once-daily topical gel.

Bausch Health (NYSE:BHC) announced significant changes in its shareholding structure and board composition. Paulson Capital Inc. and its affiliates have acquired 34,721,118 common shares previously held by Carl C. Icahn's group, increasing their beneficial ownership to approximately 19.13% of the company's outstanding shares.

Following this transaction, the Director Appointment and Nomination Agreement with the Icahn Group has terminated, leading to the resignation of Brett M. Icahn and Steven D. Miller from the Board of Directors. John A. Paulson, Chairperson of the Bausch Health Board, expressed confidence in the company's value and its efforts to maximize shareholder value.

Bausch Health (NYSE:BHC) has announced the winners of its 2025 Salix Gastrointestinal Health Scholars Program. The company awarded $10,000 scholarships to 10 students living with GI diseases, marking the sixth consecutive year of the program. Selected from over 370 applicants, recipients were chosen across three categories: Undergraduate Scholar Awards, Graduate Scholar Awards, and Working and/or Single Parent's Scholar Award.

The scholarship program aims to support students pursuing higher education while managing gastrointestinal conditions. Recipients were selected based on personal essays describing how their GI conditions have influenced their educational journey and the support received from healthcare providers.

Bausch Health (NYSE:BHC) reported strong Q2 2025 financial results with consolidated revenues of $2.53 billion, up 5% year-over-year. The company achieved GAAP Net Income of $148 million and Adjusted EBITDA of $842 million, marking its ninth consecutive quarter of growth.

Key segment performance includes Salix segment growth of 12% driven by Xifaxan®, Solta Medical segment growth of 25%, and Bausch + Lomb segment growth of 5%. The company announced plans to repay approximately $900 million in debt and entered an agreement to acquire DURECT Corporation to expand its hepatology portfolio.

Management reaffirmed its full-year 2025 guidance, projecting consolidated revenues of $10.0-10.25 billion and Adjusted EBITDA of $3.485-3.635 billion.

Bausch Health (NYSE:BHC) has announced a definitive agreement to acquire DURECT Corporation (NASDAQ:DRRX) in a deal valued at approximately $63 million upfront, with potential additional milestone payments of up to $350 million. The acquisition price represents a 217% premium to DURECT's closing price.

The key asset in this acquisition is larsucosterol, an epigenetic modulator with FDA Breakthrough Therapy Designation for treating alcoholic hepatitis (AH). The drug has shown promising results in Phase 2 trials and addresses a significant unmet medical need, as AH accounts for 164,000 hospital admissions in the U.S. annually with no FDA-approved treatments currently available.

The transaction is expected to close in Q3 2025, subject to customary conditions including majority shareholder tender. The deal complements Bausch Health's existing hepatology portfolio, particularly their Phase 3 rifaximin SSD program.